

4DMedical wins commercial contract with Intermountain Health

5 May 2025

Highlights

- Contract win with Intermountain Health, a major U.S. health system headquartered in Utah
 - Contract for deployment of 4DMedical's recently FDA-cleared Pulmonary Hypertension Analysis (PHA™) product
 - Sale won via 4DMedical's strategic distribution partnership with Nuance Communications, a Microsoft-owned company
-

Melbourne, Australia, 5 May 2025: 4DMedical Limited (ASX: 4DX, "4DMedical", or the "Company"), a global leader in respiratory imaging technology, today announces the execution of a commercial contract with Intermountain Health, a major U.S. health system headquartered in Utah, for the implementation of 4DMedical's recently FDA-cleared Pulmonary Hypertension Analysis (PHA™) product.

4DMedical secures commercial contract with Intermountain Health

Intermountain Health is a U.S. health system consisting of 33 hospitals, 400 clinics, and includes nearly 4,000 physicians. Serving communities across Utah, Idaho, Nevada, Colorado, and Montana, Intermountain Health is widely regarded as a leader in value-based care, innovation, and the early adoption of advanced technologies that improve patient outcomes.

Intermountain Health's scale and clinical excellence provides an ideal launchpad for 4DMedical's PHA™ product, which is an AI-based algorithm designed for use in acute care settings, supporting Pulmonary Embolism Response Teams (PERTs) in the rapid assessment of pulmonary hypertension secondary to pulmonary embolism (PE). It provides automated measurements of right ventricle (RV) and main pulmonary artery diameters, along with clinically relevant ratios, which serve as key indicators of pulmonary hypertension resulting from PE-related thrombus.

Nuance partnership

The contract was secured through Nuance Communications, a Microsoft-owned company, as part of 4DMedical's strategic distribution partnership. Nuance provides AI-driven clinical documentation and diagnostic imaging solutions to healthcare providers across the United States.

This agreement represents the first major deployment of 4DMedical's PHA™ algorithm within a large, integrated health network, and highlights the commercial advantages enabled by 4DMedical's distribution agreement with Nuance's nationwide network. The PHA™ algorithm integrates seamlessly into existing radiology workflows via Nuance's PowerScribe platform, enabling enhanced clinical decision-making.

Intermountain Health is one of three Microsoft Innovation Sites in the United States. Under the terms of the Innovation Site agreement the first year's payment by Intermountain Health to Nuance is fixed, at a price that represents only a small volume of scans. However, in future years the payments will build to the number of scans in use across the 33 hospitals in the system, thereby representing a significant opportunity.

Melbourne

Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles

21255 Burbank Boulevard
Suite 120
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com



4DMedical MD/CEO and Founder Andreas Fouras said:

We are thrilled to partner with Intermountain Health through our distribution agreement with Nuance. Intermountain's leadership in data-driven, high-quality care makes them an ideal partner to lead this important innovation in cardio-pulmonary health care delivery.

This contract establishes us within a health system of 33 hospitals and nearly 4,000 physicians. As the contract transitions to full commercial terms this revenue stream will become meaningful for us. Furthermore, under those terms we can grow revenue through increased usage of PHA™ and expansion to other products in the portfolio, further growing the opportunity within this large health system.

4D stands at a very exciting moment, with rapid growth in sites and scans month on month. This growth is soon to be boosted as our investment in the relationship with Philips matures, and preparations for the CT:VQ™ submission to the FDA for 510(k) clearance nears completion, paving the way for market entry later in CY2025.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

4Dmedia@4dmedical.com

About 4DMedical

4DMedical Limited (ASX:4DX) is a cutting-edge global medical technology company revolutionizing respiratory care. By harnessing advanced imaging and AI-powered solutions, 4DMedical delivers unprecedented insights into lung function, enabling earlier and more precise diagnoses of respiratory diseases.

At the heart of 4DMedical's innovation is its patented XV Technology®, a groundbreaking platform that dynamically quantifies ventilation throughout the lungs as patients breathe. This technology underpins the company's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and its CT LVAS™, empowering physicians to detect and monitor regional airflow abnormalities with unparalleled sensitivity.

4DMedical's solutions integrate seamlessly into existing hospital infrastructure via its Software as a Service (SaaS) model, transforming routine imaging into powerful diagnostic tools.

In December 2023, 4DMedical expanded its leadership in medical imaging with the acquisition of **Imbio**, a pioneer in artificial intelligence solutions for chronic lung and cardiothoracic diseases. Imbio's AI-driven platforms enhance physician productivity, improve diagnostic precision, and support personalized care, aligning seamlessly with 4DMedical's mission to redefine respiratory healthcare.

To learn more, please visit www.4dmedical.com